Theravance Biopharma (TBPH) Other Accumulated Expenses (2013 - 2026)

Theravance Biopharma (TBPH) has 14 years of Other Accumulated Expenses data on file, last reported at $988000.0 in Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $988000.0, down 52.29% year-over-year; the trailing twelve-month figure through Mar 2026 was $988000.0 (down 52.29% YoY), and the FY2025 annual result was $1.5 million, down 32.93% from the prior year.
• Other Accumulated Expenses retreated to $988000.0 in Q1 2026 per TBPH's latest filing, from $1.5 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $2.3 million in Q2 2022 and troughed at $142000.0 in Q3 2022.
• A 5-year average of $1.4 million and a median of $1.3 million in 2025 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2023: Other Accumulated Expenses plunged 92.24% in 2022, then soared 963.38% in 2023.
• A 5-year view of Other Accumulated Expenses shows it stood at $1.1 million in 2022, then increased by 8.67% to $1.2 million in 2023, then surged by 78.4% to $2.2 million in 2024, then sank by 32.93% to $1.5 million in 2025, then tumbled by 33.47% to $988000.0 in 2026.
• Business Quant data shows TBPH's Other Accumulated Expenses at $988000.0 in Q1 2026, $1.5 million in Q4 2025, and $1.3 million in Q3 2025.